XML 20 R6.htm IDEA: XBRL DOCUMENT v3.26.1
Consolidated Statements of Total Equity - USD ($)
$ in Thousands
Total
Common Stock [Member]
Additional Paid-in Capital [Member]
AOCI Attributable to Parent [Member]
Retained Earnings [Member]
Parent [Member]
Noncontrolling Interest [Member]
Balance at Dec. 31, 2023 $ (8,235) $ 91,384 $ (47) $ (99,572) $ (8,235)
Balance, shares at Dec. 31, 2023   296,019          
Exercise of pre-funded warrants 2 2 2
Exercise of pre-funded warrants, shares   16,375          
Issuance of common stock through May Inducement Offer, net of financing costs 1,818 1,818 1,818
Issuance of common shares through May Inducement Offer, net of financing costs, shares   89,151          
Stock-based compensation 2,957 2,957 2,957
Foreign currency translation adjustments 19 19 19
Net loss (22,209) (22,143) (22,143) (66)
Balance at Dec. 31, 2024 1,968 123,277 (28) (121,715) 1,534 434
Balance, shares at Dec. 31, 2024   1,730,051          
Issuance of common stock in lieu of cash for services 369 369 369
Issuance of common stock in lieu of cash for services, shares   14,589,000          
Issuance of common stock in lieu of cash for SEPA commitment fee 81 81 81
Issuance of common stock in lieu of cash for commitment fee, shares   1,157,000          
Issuance of common stock to Calidi stockholders as result of Merger
Issuance of common stock to Calidi stockholders as result of Merger, shares   132          
Financing fees (327) (327) (327)
Issuance of common stock and pre-funded warrants through April Public Offering, net of financing costs 4,822 4,822 4,822
Issuance of common shares and pre-funded warrants through April Public Offering, net of financing costs, shares   110,271          
Issuance of common stock per Convertible Note conversion 3,071 3,071 3,071
Issuance of common stock per Convertible Note conversion, shares   176,731          
Exercise of common stock warrants 4,803 4,803 4,803
Exercise of common stock warrants, shares   256,886          
Issuance of restricted stock units for liability settlement 133 133 133
Issuance of common stock and warrants for legal settlement 308 308 308
Issuance of common stock and warrants for legal settlement, shares   1,667          
Issuance of common stock for Reverse Stock Split fractional shares
Issuance of common stock for Reverse Stock Split fractional shares, shares   6,621          
Issuance of common stock and warrants per subscription agreement 1,000 1,000 1,000
Issuance of common shares and warrants per subscription agreement, shares   58,235          
Issuance of common stock and warrants for registered direct offering 1,631 1,631 1,631
Issuance of common stock and warrants for registered direct offering, shares   170,834          
Issuance of common stock through At the Market Offering 3,063 3,063 3,063
Issuance of common stock through At the Market Offering, shares   158,355          
Issuance of common stock through November Public Offering, net of financing 6,662 6,662 6,662
Issuance of common stock through November Public Offering, net of financing, shares   369,823          
Investment in Nova Cell 2,000 1,500 1,500 500
Restricted stock unit shares released
Restricted stock unit shares released, shares   3,205          
Issuance of common stock through At the Market Offering 3,201 3,201 3,201
Issuance of common stock through At the Market Offering, shares   534,265          
Issuance of common stock and warrants through January Confidentially Marketed Public Offering, net of financing costs 3,607 3,607 3,607
Issuance of common stock and warrants through January Confidentially Marketed Public Offering, net of financing costs, shares   416,667          
Issuance of common stock and warrants for March Registered Direct Offering and Concurrent Private Placement, net of financing costs $ 3,423 $ 3,423 $ 3,423
Issuance of common stock and warrants for March Registered Direct Offering and Concurrent Private Placement, net of financing costs, shares   277,084          
Issuance of common stock through August Public Offering 5,768,000 1,000 5,767,000 5,768,000
Issuance of common stock through August Public Offering, shares   1,922,764          
Exercise of pre-funded warrants $ 5 $ 5 $ 5
Exercise of pre-funded warrants, shares   1,759,500          
Issuance of common stock through May Inducement Offer, net of financing costs 4,004 4,004 4,004
Issuance of common shares through May Inducement Offer, net of financing costs, shares   549,596          
Issuance of common stock for Reverse Stock Split fractional shares
Issuance of common stock for Reverse Stock Split fractional shares, shares   25,029          
Restricted stock unit shares released
Restricted stock unit shares released, shares   2,038          
Sale of investment in Nova Cell (277) (277)
Stock-based compensation 2,108 2,108 2,108
Foreign currency translation adjustments 15 15 15
Net loss (20,063) (19,906) (19,906) (157)
Balance at Dec. 31, 2025 $ 3,759 $ 1 $ 145,392 $ (13) $ (141,621) $ 3,759
Balance, shares at Dec. 31, 2025   7,216,994